Departments of Radiology and Epidemiology, University of North Carolina, Chapel Hill, NC.
Department of Surgery, University of Washington, Seattle, WA.
Chest. 2022 Mar;161(3):826-832. doi: 10.1016/j.chest.2021.11.010. Epub 2021 Nov 18.
Pretreatment invasive nodal staging is paramount for appropriate treatment decisions in non-small cell lung cancer. Despite guidelines recommending when to perform staging, many studies suggest that invasive nodal staging is underused. Attitudes and barriers to guideline-recommended staging are unclear. The National Lung Cancer Roundtable initiated this study to better understand the factors associated with guideline-adherent nodal staging.
What are the knowledge gaps, attitudes, and beliefs of thoracic surgeons and pulmonologists about invasive nodal staging? What are the barriers to guideline-recommended staging?
A web-based survey of a random sample of pulmonologists and thoracic surgeons identified as members of American College of Chest Physicians (CHEST) was conducted in 2019. Survey domains included knowledge of invasive nodal staging guidelines, attitudes and beliefs toward implementation, and perceived barriers to guideline adherence.
Among 453 responding physicians, 29% were unaware that invasive nodal staging guidelines exist. Among the 320 physicians who knew guidelines exist, attitudes toward the guidelines were favorable, with 91% agreeing guidelines are generalizable and 90% agreeing that recommendations improved their staging and treatment decisions. Approximately 80% responded that guideline recommendations are based on satisfactory levels of scientific evidence, and 50% stated a lack of evidence linking adherence to guidelines to changes in management or better patient outcomes. Nearly 9 in 10 physicians reported at least one barrier to guideline adherence. The most common barriers included patient anxiety associated with treatment delays (62%), difficulty implementing guidelines into routine practice (52%), and time delays of additional testing (51%).
Among physicians who responded to our survey, more than one-quarter were unaware of invasive nodal staging guidelines. Attitudes toward guideline recommendations were positive, although 20% reported insufficient evidence to support staging algorithms. Most physicians reported barriers to implementing guidelines. Multilevel interventions are likely needed to increase rates of guideline-recommended invasive nodal staging.
在非小细胞肺癌中,治疗前的侵袭性淋巴结分期对于做出恰当的治疗决策至关重要。尽管指南建议何时进行分期,但许多研究表明侵袭性淋巴结分期的应用不足。对于指南推荐的分期,医生的态度和障碍尚不清楚。为了更好地了解与遵循指南的淋巴结分期相关的因素,美国国家肺癌圆桌会议发起了这项研究。
胸外科医生和肺病学家对侵袭性淋巴结分期的知识差距、态度和信念是什么?推荐的分期存在哪些障碍?
2019 年,对美国胸科学会(CHEST)成员中的随机抽取的胸外科医生和肺病学家进行了一项基于网络的调查。调查内容包括对侵袭性淋巴结分期指南的了解、对实施的态度和信念,以及对遵循指南的障碍的看法。
在 453 名回应的医生中,29%的人不知道存在侵袭性淋巴结分期指南。在 320 名知道指南存在的医生中,他们对这些指南的态度是积极的,91%的人认为这些指南具有普遍性,90%的人认为这些建议改善了他们的分期和治疗决策。大约 80%的人表示指南推荐是基于令人满意的科学证据水平,而 50%的人表示缺乏将遵循指南与管理方式的改变或更好的患者结果联系起来的证据。近 9 成的医生报告了至少一个阻碍遵循指南的障碍。最常见的障碍包括与治疗延迟相关的患者焦虑(62%)、难以将指南纳入常规实践(52%),以及额外检测的时间延迟(51%)。
在对我们的调查做出回应的医生中,超过四分之一的人不知道侵袭性淋巴结分期指南。尽管对指南推荐的态度是积极的,但 20%的人报告说没有足够的证据支持分期算法。大多数医生报告了实施指南的障碍。可能需要采取多层次的干预措施来提高推荐的侵袭性淋巴结分期的比率。